The European Medicines Agency is this week set to decide whether to recommend pan-EU marketing approval for a number of new drugs, including abaloparatide, Radius Health’s osteoporosis treatment that the agency had previously rejected.
Tabelecleucel (tab‐cel), Atara Biotherapeutics’ investigational advanced therapy for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) is another product...








